Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

Logan, M. , Mackinder, M., Clark, C. M., Kountouri, A., Jere, M., Ijaz, U. Z. , Hansen, R., McGrogan, P., Russell, R. K. and Gerasimidis, K. (2022) Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease. BMC Gastroenterology, 22, 260. (doi: 10.1186/s12876-022-02334-6) (PMID:35606704) (PMCID:PMC9125891)

[img] Text
270913.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Background: There is a clinical need to develop biomarkers of small bowel damage in coeliac disease and Crohn’s disease. This study evaluated intestinal fatty acid binding protein (iFABP), a potential biomarker of small bowel damage, in children with coeliac disease and Crohn’s disease. Methods: The concentration iFABP was measured in plasma and urine of children with ulcerative colitis, coeliac disease, and Crohn’s disease at diagnosis and from the latter two groups after treatment with gluten free diet (GFD) or exclusive enteral nutrition (EEN), respectively. Healthy children (Controls) were also recruited. Results: 138 children were recruited. Plasma but not urinary iFABP was higher in patients with newly diagnosed coeliac disease than Controls (median [Q1, Q3] coeliac disease: 2104 pg/mL 1493, 2457] vs Controls: 938 pg/mL [616, 1140], p = 0.001). Plasma or urinary iFABP did not differ between patients with coeliac on GFD and Controls. Baseline iFABP in plasma decreased by 6 months on GFD (6mo GFD: 1238 pg/mL [952, 1618], p = 0.045). By 12 months this effect was lost, at which point 25% of patients with coeliac disease had detectable gluten in faeces, whilst tissue transglutaminase IgA antibodies (TGA) continued to decrease. At diagnosis, patients with Crohn’s disease had higher plasma iFABP levels than Controls (EEN Start: 1339 pg/mL [895, 1969] vs Controls: 938 pg/mL [616, 1140], p = 0.008). iFABP did not differ according to Crohn’s disease phenotype. Induction treatment with EEN tended to decrease (p = 0.072) iFABP in plasma which was no longer different to Controls (EEN End: 1114 pg/mL [689, 1400] vs Controls: 938 pg/mL [616, 1140], p = 0.164). Plasma or urinary iFABP did not differ in patients with ulcerative colitis from Controls (plasma iFABP, ulcerative colitis: 1309 pg/mL [1005, 1458] vs Controls: 938 pg/mL [616, 1140], p = 0.301; urinary iFABP ulcerative colitis: 38 pg/mg [29, 81] vs Controls: 53 pg/mg [27, 109], p = 0.605). Conclusions: Plasma, but not urinary iFABP is a candidate biomarker with better fidelity in monitoring compliance during GFD than TGA. The role of plasma iFABP in Crohn’s disease is promising but warrants further investigation.

Item Type:Articles
Additional Information:ML PhD studentship was funded by the Engineering and Physical Sciences Research Council and Nestle Health Science though they had no impact on study design, analysis or conclusions reached. UZI is supported by NERC Independent Research Fellowship NE/L011956/1.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Hansen, Dr Richard and Russell, Dr Richard and Logan, Dr Michael and Clark, Clare and Mackinder-Jonas, Mary and Gerasimidis, Professor Konstantinos and Ijaz, Dr Umer
Authors: Logan, M., Mackinder, M., Clark, C. M., Kountouri, A., Jere, M., Ijaz, U. Z., Hansen, R., McGrogan, P., Russell, R. K., and Gerasimidis, K.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
College of Science and Engineering > School of Engineering > Infrastructure and Environment
Journal Name:BMC Gastroenterology
Publisher:BioMed Central
ISSN:1471-230X
ISSN (Online):1471-230X
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in BMC Gastroenterology 22:260
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
170256Understanding microbial community through in situ environmental 'omic data synthesisUmer Zeeshan IjazNatural Environment Research Council (NERC)NE/L011956/1ENG - Infrastructure & Environment